Delavirdine mesylate is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).

Dapivirine is an inhibitor of HIV reverse transcriptase with IC50 of 24 nM which is effective for many types of viruses.

Efavirenz is an inhibitor of wild-type HIV-1 reverse transcriptase with Ki of 2.93 nM and the IC95 of its replicative spread is 1.5 nM in cell culture.

Nevirapine is an inhibitor of reverse transcriptase which is used in combination with nucleoside analogues to treat HIV-1 infection.

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) with anti-HIV effect.

Etravirine is an inhibitor of non-nucleoside reverse transcriptase used to treat HIV.

Lersivirine is a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI, IC50=119 nM) with a unique resistance profile that exhibits potent antiretroviral activity against wild-type human immunodeficiency virus and clinically relevant NNRTI-resistant strains.

Elsulfavirine is a new-generation and long-half-life NNRT inhibitor for the treatment and prevention of HIV infections.

Dexelvucitabine is a nucleoside reverse transcriptase inhibitor potentially for the treatment of HIV infection.

Etravirine D4 is the deuterium labeled Etravirine, which is a NNRTI used for the treatment of HIV.

Delavirdine is a potent non-nucleoside reverse transcriptase inhibitor (NNRTI).

Tomeglovir, a non-nucleoside antiviral, protects against cytomegalovirus (CMV) disease and mortality in immunocompromised guinea pigs.

MK-4965 is a nonnucleoside reverse transcriptase inhibitor with anti-viral activity. MK-4965 possesses the desired properties for further development as an NNRTI for the treatment of HIV-1 infection.

Lamivudine is a nucleoside reverse transcriptase inhibitors (NRTIs)， which can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus.